title: Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial.
abstract: OBJECTIVE
  Long-term follow-up data of a randomized trial that compared hydroxyurea and the hypoxic-cell radiosensitizer to misonidazole as adjuncts to standard radiation therapy in locally advanced carcinoma of the cervix are reported.
  
  
  METHODS
  Three hundred eight women were entered, and all 294 eligible patients are assessable as randomized. Eighty-one percent of patients have been monitored for 5 years or to death.
  
  
  RESULTS
  There was an advantage for hydroxyurea in progression-free interval and survival (P = .05 and P = .066, respectively). There was no significant difference in the distribution of sites of failure between the regimens. For the 39% of patients with stages III to IVA disease, the advantage in progression-free interval for hydroxyurea was significant (47.8% v 33.6%). More leukopenia occurred on the hydroxyurea regimen than on the misonidazole regimen.
  
  
  CONCLUSIONS
  In summary, these data provide stronger evidence than our previous analysis that hydroxyurea is superior to misonidazole as an adjunct to radiation therapy. For patients with locally advanced carcinoma of the cervix, hydroxyurea continues to be the adjunct of choice with radiation.
authors.affiliation: Department of Obstetrics and Gynecology, Indiana University Medical Center, Indianapolis.
authors.forename: F B
authors.initials: FB
authors.lastname: Stehman
authors.forename: B N
authors.initials: BN
authors.lastname: Bundy
authors.forename: G
authors.initials: G
authors.lastname: Thomas
authors.forename: H M
authors.initials: HM
authors.lastname: Keys
authors.forename: G
authors.initials: G
authors.lastname: d'Ablaing
authors.forename: W C
authors.initials: WC
authors.lastname: Fowler
authors.forename: R
authors.initials: R
authors.lastname: Mortel
authors.forename: W T
authors.initials: WT
authors.lastname: Creasman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy*; D002423:Cause of Death; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D015993:Life Tables; D008875:Middle Aged; D008920:Misonidazole / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D008920:Misonidazole; D006918:Hydroxyurea